Plain-English translation of NCT06443645 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Some chemotherapy drugs used to treat breast cancer can damage the heart over time. This trial is testing whether SGLT2 inhibitors—a class of medication originally developed for diabetes—can protect your heart while you receive this chemotherapy. Researchers want to see if the medication can prevent or reduce heart injury in people being treated for breast cancer.
Heart damage from chemotherapy is a serious side effect that affects many breast cancer survivors and can limit the doses doctors can safely give. While older heart-protective medications like ACE inhibitors help somewhat, doctors need better tools to prevent this damage from happening in the first place. This study explores whether the medication might offer that extra protection.
You likely qualify if…
You likely don't qualify if…
You would take the study medication by mouth for a set period while undergoing your planned breast cancer chemotherapy. The research team will monitor your heart health through blood tests and heart imaging before, during, and after your chemotherapy to see whether the medication helps protect your heart. Regular clinic visits will track how you're doing and watch for any side effects.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
France